IJCS | Volume 32, Nº1, January/ February 2019

82 15. Fallavollita JA, Malm BJ, Canty JM Jr. Hibernating myocardium retains metabolic and contractile reserve despite regional reductions in flow, function, and oxygen consumption at rest. Circ Res. 2003;92(1):48-55. 16. Sinusas AJ, Watson DD, Cannon JM, Beller GA. Effect of ischemia and postischemic dysfunction on myocardial uptake of technetium-99m- labeled methoxyisobutyl isonitrile and thallium-201. J Am Coll Cardiol 1989;14(7):1785-93. 17. Freeman I, GrunwaldAM, Hoory S, BodenheimerMM. Effect of coronary occlusion andmyocardial viability onmyocardial activity of technetium- 99m-sestamibi. J Nucl Med Off Publ Soc Nucl Med. 1991;32(2):292-8. 18. Beanlands RS, Dawood F, WenWH, McLaughlin PR, Butany J, D'Amati G, et al. Are the kinetics of technetium-99m methoxyisobutyl isonitrile affected by cell metabolismand viability? Circulation. 1990;82(5):1802-14. 19. Kaul S. Myocardial Contrast Echocardiography a 25-year retrospective. Circulation. 2008;118(3):291-308. 20. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008;117(1):103-14. 21. Marzullo P, Parodi O, Reisenhofer B, Sambuceti G, Picano E, Distante A, et al. Value of rest thallium-201/technetium-99m sestamibi scans and dobutamine echocardiography for detecting myocardial viability. Am J Cardiol. 1993;71(2):166-72. 22. Marzullo P, Sambuceti G, Parodi O. The role of sestamibi scintigraphy in the radioisotopic assessment of myocardial viability. J Nucl Med. 1992;33(11):1925-30. 23. Sawada SG, Allman KC, Muzik O, Beanlands RS, Wolfe ER Jr, Gross M, et al. Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol. 1994;23(1):92-8. 24. Cuocolo A, Pace L, Ricciardelli B, Chiariello M, Trimarco B, Salvatore M. Identification of viable myocardium in patients with chronic coronary artery disease: comparison of thallium-201 scintigraphy with reinjection and technetium-99m-methoxyisobutyl isonitrile. J Nucl Med. 1992;33(4):505-11. 25. Dilsizian V, Arrighi JA, Diodati JG, Quyyumi AA, Alavi K, Bacharach SL, et al. Myocardial viability in patients with chronic coronary artery disease. Comparison of 99m Tc-sestamibi with thallium reinjection and [18F]fluorodeoxyglucose. Circulation. 1994;89(2):578-87. Erratum in: Circulation. 1995;91(12):3026. 26. Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation. 1991;83(1):26-37. 27. Romero J, Xue X, Gonzalez W, Garcia MJ. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysis of prospective trials. JACC Cardiovasc Imaging. 2012;5(5):494-508. 28. Schvartzman PR, Srichai MB, GrimmRA, Obuchowski NA, Hammer DF, McCarthy PM, et al. Nonstress delayed-enhancement magnetic resonance imaging of the myocardium predicts improvement of function after revascularization for chronic ischemic heart disease with left ventricular dysfunction. Am Heart J. 2003;146(3):535-41. 29. Kühl HP, Lipke CS, Krombach GA, KatohM, Battenberg TF, Nowak B, et al. Assessment of reversiblemyocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography–single photon emission computed tomography imaging protocol. Eur Heart J. 2006;27(7):846-53. 30. Rischpler C, Langwieser N, Souvatzoglou M, Batrice A, van Marwick S, Snajberk J, et al. PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake. Eur Heart J Cardiovasc Imaging. 2015;16(6):661-9. 31. Inaba Y, Chen JA, Bergmann SR. Quantity of viablemyocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: a meta-analysis. J Nucl Cardiol. 2010;17(4):646-54. 32. Mule JD, Bax JJ, Zingone B, Martinelli F, Burelli C, Stefania A, et al. The beneficial effect of revascularization on jeopardizedmyocardium: reverse remodeling and improved long-term prognosis. Eur J Cardio-Thorac Surg. 2002;22(3):426–30. 33. Tamaki N, Yonekura Y, Yamashita K, Saji H, Magata Y, Senda M, et al. Positronemissiontomographyusingfluorine-18deoxyglucoseinevaluation of coronary artery bypass grafting. Am J Cardiol. 1989;64(14):860-5. 34. Haas F, Haehnel CJ, Picker W, Nekolla S, Martinoff S, Meisner H, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30(7):1693-700. 35. BonowRO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al; STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. NEngl J Med. 2011;364(17):1617-25. 36. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation. 1994;90(6):2687-94. 37. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al; STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374(16):1511-20. 38. Siebelink HM, Blanksma PK, Crijns HJ, Bax JJ, van Boven AJ, Kingma T, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol. 2001;37(1):81-8. 39. Beanlands RS, Ruddy TD, Freeman M, Nichol G. Patient management guided by viability imaging. J Am Coll Cardiol. 2001;38(4):1271-3. 40. Mielniczuk LM, Beanlands RS. Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit?: Imaging- guided selection of patients with ischemic heart failure for high-risk revascularization improves identification of those with the highest clinical benefit. Circ Cardiovasc Imaging. 2012;5(2):262-70. 41. Shukla T, Nichol G, Wells G, deKemp RA, Davies RA, Haddad H, et al. Does FDG PET-assisted management of patients with left ventricular dysfunction improve quality of life? A substudy of the PARR-2 trial. Can J Cardiol. 2012;28(1):54-61. 42. Jacklin PB, Barrington SF, Roxburgh JC, Jackson G, Sariklis D, West PA, et al. Cost-effectiveness of preoperative positron emission tomography in ischemic heart disease. Ann Thorac Surg 2002;73(5):1403-9. 43. Mielniczuk LM, Toth GG, Xie JX, De Bruyne B, Shaw LJ, Beanlands RS. Can functional testing for ischemia and viability guide revascularization? JACC Cardiovasc Imaging. 2017;10(3):354-64. 44. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Nuclear Cardiology. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary A Report of the AmericanCollege of Cardiology/AmericanHeart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation. 2003;108(11):1404-18. 45. HendelRC,BermanDS,DiCarliMF,HeidenreichPA,HenkinRE,Pellikka PA, et al; American College of Cardiology Foundation Appropriate Use Criteria Task Force; American Society of Nuclear Cardiology; American College of Radiology; American Heart Association; American Society of Echocardiography; Society of Cardiovascular Computed Tomography; Society for Cardiovascular Magnetic Resonance; Society of Nuclear Medicine. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Erthal et al. Myocardial viability: from PARR-2 to IMAGE HF - current evidence and future directions Int J Cardiovasc Sci. 2019;32(1)70-83 Review Article